Cancer clinical trials in the region Centre-Val de Loire
111 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Prostate cancer
#NCT05116475
#2024-517285-41-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3
Pancreas cancer
#NCT00268411
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Chemotherapy
Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
Radiotherapy
14 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 2 / Phase 3
Multiple myeloma
#NCT07095452
#2025-520897-21-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required IMWG cytogenetic prognoses
High risk
15 recruiting sites
Abbvie
Phase 2 / Phase 3
Lung cancer
#NCT07063745
#2025-521511-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
13 recruiting sites
Bristol-Myers Squibb
Phase 2 / Phase 3
Head and neck cancer
#NCT04534205
#2020-001400-41
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Salivary glands
Nasal cavities and sinuses
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required P16 statuses
P16 Positive
Required CPS scores
CPS Positive (1 <= X < 20)
CPS Positive (X >= 20)
6 recruiting sites
BioNTech SE
Phase 2
Brain tumors / Central nervous system tumors
#NCT02394626
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1
Required previous treatments
Surgery
Radiotherapy
8 recruiting sites
Insel Gruppe AG, University Hospital Bern
Phase 2
Multiple myeloma
#NCT06183489
#2023-505775-70-00
Required histologic types
Smoldering multiple myeloma (SMM)
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required IMWG cytogenetic prognoses
High risk
6 recruiting sites
European Myeloma Network B.V.
Phase 2
Multiple myeloma
#NCT05572229
#2022-001594-31
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
17 recruiting sites
Hôpital universitaire de Lille
Phase 2
Lung cancer
#NCT04613596
#2023-508922-83-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 2
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT05980806
#2024-511309-47-00
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis
Secondary myelofibrosis
Required DIPSS scores
Intermediate-1
Intermediate-2
High
Excluded previous treatments
Targeted therapy
8 recruiting sites
Karyopharm Therapeutics Inc.